Maurizio Pellecchia
Maurizio Pellecchia
Verified email at - Homepage
TitleCited byYear
A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes
N Bottini, L Musumeci, A Alonso, S Rahmouni, K Nika, M Rostamkhani, ...
Nature genetics 36 (4), 337-338, 2004
NMR in drug discovery
M Pellecchia, DS Sem, K WŁthrich
Nature Reviews Drug Discovery 1 (3), 211-219, 2002
Apoptosis-based therapies for hematologic malignancies
JC Reed, M Pellecchia
Blood 106 (2), 408-418, 2005
Discovery, characterization, and structure− activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins
S Kitada, M Leone, S Sareth, D Zhai, JC Reed, M Pellecchia
Journal of medicinal chemistry 46 (20), 4259-4264, 2003
Perspectives on NMR in drug discovery: a technique comes of age
M Pellecchia, I Bertini, D Cowburn, C Dalvit, E Giralt, W Jahnke, TL James, ...
Nature Reviews Drug Discovery 7 (9), 738-745, 2008
Apoptosis-inducing factor triggered by poly (ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia
C Culmsee, C Zhu, S Landshamer, B Becattini, E Wagner, M Pellecchia, ...
Journal of Neuroscience 25 (44), 10262-10272, 2005
Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins
M Leone, D Zhai, S Sareth, S Kitada, JC Reed, M Pellecchia
Cancer Research 63 (23), 8118-8121, 2003
Role of excitatory amino acid transporter‐2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics
K Kim, SG Lee, TP Kegelman, ZZ Su, SK Das, R Dash, S Dasgupta, ...
Journal of cellular physiology 226 (10), 2484-2493, 2011
A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy
WJ Placzek, J Wei, S Kitada, D Zhai, JC Reed, M Pellecchia
Cell death & disease 1 (5), e40-e40, 2010
Structural insights into substrate binding by the molecular chaperone DnaK
M Pellecchia, DL Montgomery, SY Stevens, CW Vander Kooi, H Feng, ...
Nature structural biology 7 (4), 298-303, 2000
NMR Structure of the J-domain and the Gly/Phe-rich Region of theEscherichia coliDnaJ Chaperone
M Pellecchia, T Szyperski, D Wall, C Georgopoulos, K WŁthrich
Journal of molecular biology 260 (2), 236-250, 1996
Targeting the Bcl-2 family for cancer therapy
S Thomas, BA Quinn, SK Das, R Dash, L Emdad, S Dasgupta, XY Wang, ...
Expert opinion on therapeutic targets 17 (1), 61-75, 2013
Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-XL
B Becattini, S Kitada, M Leone, E Monosov, S Chandler, D Zhai, TJ Kipps, ...
Chemistry & biology 11 (3), 389-395, 2004
Targeting Mcl-1 for the therapy of cancer
BA Quinn, R Dash, B Azab, S Sarkar, SK Das, S Kumar, RA Oyesanya, ...
Expert opinion on investigational drugs 20 (10), 1397-1411, 2011
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site
JL Stebbins, SK De, T Machleidt, B Becattini, J Vazquez, C Kuntzen, ...
Proceedings of the National Academy of Sciences 105 (43), 16809-16813, 2008
NMR structure determination of the Escherichia coli DnaJ molecular chaperone: secondary structure and backbone fold of the N-terminal region (residues 2-108) containing the†…
T Szyperski, M Pellecchia, D Wall, C Georgopoulos, K WŁthrich
Proceedings of the National Academy of Sciences 91 (24), 11343-11347, 1994
Efficient synthetic inhibitors of anthrax lethal factor
M Forino, S Johnson, TY Wong, DV Rozanov, AY Savinov, W Li, ...
Proceedings of the National Academy of Sciences 102 (27), 9499-9504, 2005
Pilus chaperone FimC–adhesin FimH interactions mapped by TROSY-NMR
M Pellecchia, P Sebbel, U Hermanns, K WŁthrich, R Glockshuber
Nature structural biology 6 (4), 336-339, 1999
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition
DJ Goff, AC Recart, A Sadarangani, HJ Chun, CL Barrett, M Krajewska, ...
Cell stem cell 12 (3), 316-328, 2013
Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2–transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048)
S Kitada, CL Kress, M Krajewska, L Jia, M Pellecchia, JC Reed
Blood, The Journal of the American Society of Hematology 111 (6), 3211-3219, 2008
The system can't perform the operation now. Try again later.
Articles 1–20